Glibenclamide alleviates β adrenergic receptor activation-induced cardiac inflammation

被引:0
|
作者
Ning Cao
Jing-jing Wang
Ji-min Wu
Wen-li Xu
Rui Wang
Xian-da Chen
Ye-nan Feng
Wen-wen Cong
You-yi Zhang
Han Xiao
Er-dan Dong
机构
[1] Peking University Third Hospital; NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides; Key Laboratory of Molecular Cardiovascular Science,Department of Cardiology and Institute of Vascular Medicine
[2] Ministry of Education; Beijing Key Laboratory of Cardiovascular Receptors Research,Intensive Care Unit, Emergency Medical Research Institute
[3] Tianjin First Center Hospital,Ministry
[4] Shihezi University,of
来源
Acta Pharmacologica Sinica | 2022年 / 43卷
关键词
glibenclamide; cardiac inflammation; isoprenaline; sympathetic stress; NLRP3 inflammasome; adrenergic receptor;
D O I
暂无
中图分类号
学科分类号
摘要
β-Adrenergic receptor (β-AR) overactivation is a major pathological factor associated with cardiac diseases and mediates cardiac inflammatory injury. Glibenclamide has shown anti-inflammatory effects in previous research. However, it is unclear whether and how glibenclamide can alleviate cardiac inflammatory injury induced by β-AR overactivation. In the present study, male C57BL/6J mice were treated with or without the β-AR agonist isoprenaline (ISO) with or without glibenclamide pretreatment. The results indicated that glibenclamide alleviated ISO-induced macrophage infiltration in the heart, as determined by Mac-3 staining. Consistent with this finding, glibenclamide also inhibited ISO-induced chemokines and proinflammatory cytokines expression in the heart. Moreover, glibenclamide inhibited ISO-induced cardiac fibrosis and dysfunction in mice. To reveal the protective mechanism of glibenclamide, the NLRP3 inflammasome was further analysed. ISO activated the NLRP3 inflammasome in both cardiomyocytes and mouse hearts, but this effect was alleviated by glibenclamide pretreatment. Furthermore, in cardiomyocytes, ISO increased the efflux of potassium and the generation of ROS, which are recognized as activators of the NLRP3 inflammasome. The ISO-induced increases in these processes were inhibited by glibenclamide pretreatment. Moreover, glibenclamide inhibited the cAMP/PKA signalling pathway, which is downstream of β-AR, by increasing phosphodiesterase activity in mouse hearts and cardiomyocytes. In conclusion, glibenclamide alleviates β-AR overactivation-induced cardiac inflammation by inhibiting the NLRP3 inflammasome. The underlying mechanism involves glibenclamide-mediated suppression of potassium efflux and ROS generation by inhibiting the cAMP/PKA pathway.
引用
收藏
页码:1243 / 1250
页数:7
相关论文
共 50 条
  • [21] Role of Activation-Induced Cytidine Deaminase in Inflammation-Associated Cancer Development
    Marusawa, Hiroyuki
    Takai, Atsushi
    Chiba, Tsutomu
    ADVANCES IN IMMUNOLOGY, VOL 111, 2011, 111 : 109 - 141
  • [22] Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma
    Komori, Junji
    Marusawa, Hiroyuki
    Machimoto, Takafumi
    Endo, Yoko
    Kinoshita, Kazuo
    Kou, Tadayuki
    Haga, Hironori
    Ikai, Iwao
    Uemoto, Shinji
    Chiba, Tsutomu
    HEPATOLOGY, 2008, 47 (03) : 888 - 896
  • [23] Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer
    Mechtcheriakova, Diana
    Svoboda, Martin
    Meshcheryakova, Anastasia
    Jensen-Jarolim, Erika
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (09) : 1591 - 1598
  • [24] Activation-induced cytidine deaminase links ovulation-induced inflammation and serous carcinogenesis.
    Sapoznik, Stav
    Bahar-Shany, Keren
    Brand, Hadar
    Pinto, Yishay
    Gabay, Orshay
    Glick-Saar, Efrat
    Dor, Chen
    Zadok, Oranit
    Barshack, Iris
    Zundelevich, Adi
    Gal-Yam, Einav Nili
    Yung, Yuval
    Hourvitz, Ariel
    Korach, Jacob
    Beiner, Mario
    Jacob, Jasmine
    Levanon, Erez Y.
    Barak, Michal
    Aviel-Ronen, Sarit
    Levanon, Keren
    CLINICAL CANCER RESEARCH, 2016, 22
  • [25] BIGLYCAN, A NEWLY IDENTIFIED MEDIATOR OF MINERALOCORTICOID RECEPTOR ACTIVATION-INDUCED NEPHROPATHY
    Nakamura, Toshifumi
    Bonnard, Benjamin
    Ramirez, Roberto Palacios
    Fernandez Celis, Amaya
    Jaisser, Frederic
    Lopez Andres, Natalia
    JOURNAL OF HYPERTENSION, 2023, 41 : E378 - E378
  • [26] ADP-DEPENDENCE OF PLATELET ACTIVATION-INDUCED BY A THROMBIN RECEPTOR AGONIST
    SAVI, P
    DOL, F
    HERBERT, JM
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1993, 35 (02): : 115 - 119
  • [27] Regulation of T cell receptor signaling by activation-induced zinc influx
    Yu, Mingcan
    Lee, Won-Woo
    Tomar, Deepak
    Pryshchep, Sergey
    Czesnikiewicz-Guzik, Marta
    Lamar, David L.
    Li, Guangjin
    Singh, Karnail
    Tian, Lu
    Weyand, Cornelia M.
    Goronzy, Joerg J.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 208 (04): : 775 - 785
  • [28] Activation-induced cell death
    Budd, RC
    CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (03) : 356 - 362
  • [29] ACTIVATION-INDUCED APOPTOSIS IN LYMPHOCYTES
    GREEN, DR
    SCOTT, DW
    CURRENT OPINION IN IMMUNOLOGY, 1994, 6 (03) : 476 - 487
  • [30] Targeting the E Prostanoid Receptor EP4 Mitigates Cardiac Fibrosis Induced by β-Adrenergic Activation
    Xu, Hu
    Mao, Xiuhui
    Wang, Yali
    Zhu, Chunhua
    Liang, Bo
    Zhao, Yihang
    Zhou, Mengfei
    Ye, Lan
    Hong, Mengting
    Shao, Huishu
    Wang, Yashuo
    Li, Haonan
    Qi, Yinghui
    Yang, Yongliang
    Chen, Lihong
    Guan, Youfei
    Zhang, Xiaoyan
    ADVANCED SCIENCE, 2025, 12 (12)